55.75

0.52% -0.29

After Hours: 55.75

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $55.75, with a volume of 1.68M. It is down -0.52% in the last 24 hours and down -0.14% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Previous Close:

$56.04

Open:

$57.3

24h Volume:

1.68M

Relative Volume:

0.71

Market Cap:

$8.53B

Revenue:

$700.35M

Net Income/Loss:

$461.90M

P/E Ratio:

19.43

EPS:

2.8696

Net Cash Flow:

$-14.19M

1W Performance:

+3.32%

1M Performance:

-0.14%

6M Performance:

+81.01%

1Y Performance:

+51.08%

1-Day Range:

$55.60

$57.58

1-Week Range:

$51.28

$57.58

52-Week Range:

$25.28

$59.30

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

399

Twitter

@TGTherapeutics

Next Earnings Date

2026-08-03

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	55.75	8.58B	700.35M	461.90M	-14.19M	2.8696
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Resumed	H.C. Wainwright	Buy
Jul-10-25	Resumed	Goldman	Neutral
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

02:40 AM

TGTX Maintains Buy Rating -- Price Target Raised to $86.00 by B. Riley Securities - GuruFocus

02:40 AM

11:49 AM

META_TITLE_QUOTE - Yahoo Finance

11:49 AM

10:00 AM

TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance

10:00 AM

07:55 AM

B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating - marketscreener.com

07:55 AM

06:49 AM